Favorable FDA Panel Reviews Propel Biomet, Cyberonics Stocks In June
This article was originally published in The Gray Sheet
Executive Summary
Biomet shares climbed 10.8% in June, spurred by completion of a $280 mil. Interpore Cross acquisition and investor confidence in future knee sales growth
You may also be interested in...
Thoratec May Be Acquisition Target For Firm With Access To Cardiologists
Thoratec may seek to be acquired by a larger cardiac rhythm management or heart surgery concern to help bolster referrals for its HeartMate left-ventricular assist device (LVAD) destination therapy
Cyberonics’ VNS Therapy Approvable As Last-Resort Depression Fix – Panel
FDA's Neurological Devices Panel set aside its desire for an additional, randomized trial of Cyberonics' VNS Therapy depression indication at a June 15 meeting to review the device in Gaithersburg, Md
Biomet’s Interpore Purchase Creates $200 Mil. Spinal Devices Business
Biomet will expand its spinal franchise by nearly one third and gain artificial disc technology via the $280 mil. cash acquisition of Interpore, announced March 8